% | $
Quotes you view appear here for quick access.

Transkaryotic Therapies (TKTX) Message Board

  • aceputseller2000 aceputseller2000 Apr 26, 2005 9:24 PM Flag

    morgan stanley loves deal

    Shire Deal 'Value Enhancing' - Analyst

    Monday, April 25, 2005 3:49:05 AM ET
    Dow Jones Newswires

    0744 GMT [Dow Jones] Morgan Stanley surprised by Shire Pharmaceuticals (SHPGY) share price drop on Transkaryotic Therapies acquisition. Says analysis suggests deal "could be highly value enhancing." Notes deal will strengthen Shire's existing renal and hematology product offering, and that all of Transkaryotic's products have "long periods of exclusivity, a feature that Shire's product portfolio has historically lacked." Is advisor to Shire, thus no rating. Shire +0.6% at 542p.